Aligning Clinical Trial Reporting: A systematic analysis and position statement by the International Consortium for MDS

Variability in how clinical trial elements are reported can hinder accurate interpretation and comparison of trial results. Here, we systematically analyzed published manuscripts of therapeutic clinical trials in myelodysplastic syndromes/neoplasms (MDS) focusing on how key data elements were reported and made recommendations on how to improve this reporting. We included peer-reviewed full text manuscripts that reported results of clinical trials in MDS and were published between January 1, 2015 to December 31, 2024. We analyzed the presence or absence of several pre-determined key reporting elements and then synthesized these data to evaluate for consistency across manuscripts. We identified substantial variability in descriptions of patient characteristics, as well as the definitions used for response criteria. For example, baseline ANC was reported in only 16% of lower-risk MDS studies and 23% of higher-risk MDS studies, while baseline bone marrow blast percentage was reported in only 55% of higher-risk MDS manuscripts. In addition, response endpoints lacked standardization, with six unique definitions of RBC transfusion independence identified in lower-risk MDS trials and seven different definitions of overall response rate identified in higher-risk MDS trials. Informed by the results of this analysis, we then performed a modified-Delphi process for members of the International Consortium for MDS (icMDS) to develop consensus-based recommendations for consistent and accurate reporting of MDS clinical trial results. We advocate that these recommendations serve as benchmarks and templates for clinical trial reporting in MDS to improve interpretability and comparison of results.

Authors

Institutions

Publication Details

Journal
Blood
Published
2026-11-13
DOI
https://doi.org/10.1182/blood.2026035348
Primary Topic
Meta-analysis and systematic reviews
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Aligning Clinical Trial Reporting: A systematic analysis and position statement by the International Consortium for MDS

Andrew H. Wei, Lionel Adès, Aref Al‐Kali, María E. Figueroa et al.
2 links
Blood
Meta-analysis and systematic reviews
article

Aligning Clinical Trial Reporting: A systematic analysis and position statement by the International Consortium for MDS

Andrew H. Wei, Lionel Adès, Aref Al‐Kali, María E. Figueroa, Andrew Mark Brunner, Rami S. Komrokji, Gail J. Roboz, Uma Borate, Arjan A. van de Loosdrecht, Pierre Fenaux, Ιoannis Kotsianidis, Hetty E. Carraway, Jane E. Churpek, Stephen D. Nimer, Ted M. Getz, Fabio Efficace, Omar Ibrahim Abdel-Wahab, Klaus Hans Metzeler, Robert Paul Hasserjian, David Andrew Sallman, Naval Guastad Daver, Amy Elizabeth Dezern, Daniel T. Starczynowski, Tariq Zuheir Kewan, Peter L. Greenberg, Eric Padron, Jacqueline Boultwood, Rena J. Buckstein, Marie Sébert, Shahram Y. Kordasti, Zhuoer Xie, Michael Robert Savona, Richard F. Little, Guillermo Francisco Sanz, Lisa Pleyer, Stephanie Halene, Mikkael Aaron Sekeres, Sanam Loghavi, Tae Kon Kim, Carmelo Gurnari, Olatoyosi M. Odenike, Elizabeth A. Griffiths, Christopher Simon Hourigan, Rafael L. Bejar, John M. Bennett, Katharina S. S. Götze, Amer Methqal Zeidan, Yasushi Miyazaki, Abdulraheem Yacoub, Mrinal M. Patnaik, Uwe Platzbecker, Robert Coleman Lindsley, Thomas Cluzeau, Francesc Gessé Solé, Jan Philipp Bewersdorf, Justin Taylor, Adrián Mosquera Orgueira, David P. Steensma, Matteo Giovanni Della Porta, Yazan F. Madanat, Valeria Santini, Steven D. Gore, Ghulam Jeelani Mufti, Kelly Pugh, Anne Sophie Platzbecker, Maximilian Stahl, Alan F. List, Bing Li, Mina L. Xu
article en

Abstract

Variability in how clinical trial elements are reported can hinder accurate interpretation and comparison of trial results. Here, we systematically analyzed published manuscripts of therapeutic clinical trials in myelodysplastic syndromes/neoplasms (MDS) focusing on how key data elements were reported and made recommendations on how to improve this reporting. We included peer-reviewed full text manuscripts that reported results of clinical trials in MDS and were published between January 1, 2015 to December 31, 2024. We analyzed the presence or absence of several pre-determined key reporting elements and then synthesized these data to evaluate for consistency across manuscripts. We identified substantial variability in descriptions of patient characteristics, as well as the definitions used for response criteria. For example, baseline ANC was reported in only 16% of lower-risk MDS studies and 23% of higher-risk MDS studies, while baseline bone marrow blast percentage was reported in only 55% of higher-risk MDS manuscripts. In addition, response endpoints lacked standardization, with six unique definitions of RBC transfusion independence identified in lower-risk MDS trials and seven different definitions of overall response rate identified in higher-risk MDS trials. Informed by the results of this analysis, we then performed a modified-Delphi process for members of the International Consortium for MDS (icMDS) to develop consensus-based recommendations for consistent and accurate reporting of MDS clinical trial results. We advocate that these recommendations serve as benchmarks and templates for clinical trial reporting in MDS to improve interpretability and comparison of results.

Blood
University of Rome Tor Vergata (IT), Cincinnati Children's Hospital Medical Center (US), Roswell Park Comprehensive Cancer Center (US), Cleveland Clinic (US), The Royal Melbourne Hospital (AU), Sunnybrook Health Science Centre (CA), Mayo Clinic (US), Memorial Sloan Kettering Cancer Center (US), Humanitas University (IT), The University of Texas MD Anderson Cancer Center (US), University of Wisconsin–Madison (US), Johns Hopkins University (US), University of Miami (US), Democritus University of Thrace (GR), Inserm (FR), King's College London (GB), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Vanderbilt University (US), Université Paris Cité (FR), Cornell University (US), Paracelsus Medical University (AT), The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US), Peter MacCallum Cancer Centre (AU), University of Rochester Medical Center (US), Centre Hospitalier Universitaire de Nice (FR), Moffitt Cancer Center (US), Yale University (US), University of California San Diego (US), University of Oxford (GB), University of Chicago (US), Génomes, biologie cellulaire et thérapeutiques (FR), NYU Langone Health (US), Massachusetts General Hospital (US), Josep Carreras Leukaemia Research Institute (ES), Complejo Hospitalario Universitario de Santiago (ES), Assistance Publique – Hôpitaux de Paris (FR), The University of Kansas Cancer Center (US), Fondazione Gimema Onlus (IT), Dana-Farber Cancer Institute (US), University Hospital Leipzig (DE), University of Kansas Medical Center (US), National Cancer Institute (US), Hôpital Saint-Louis (FR), Institute of Hematology & Blood Diseases Hospital (CN), Sylvester Comprehensive Cancer Center (US), University Hospital of Alexandroupolis (GR), University Hospital Carl Gustav Carus (DE), IRCCS Humanitas Research Hospital (IT), Sidney Kimmel Comprehensive Cancer Center (US), Instituto de Investigación Sanitaria La Fe (ES), Nagasaki University (JP), Weill Cornell Medicine (US), Vanderbilt-Ingram Cancer Center (US), Stanford Cancer Institute (US), Atomic Bomb Disease Institute, Nagasaki University (JP), University of Florence (IT), The Ohio State University (US), Technical University of Munich (DE), Virginia Tech (US), The University of Texas Southwestern Medical Center (US), Vanderbilt University Medical Center (US), Amsterdam UMC Location Vrije Universiteit Amsterdam (NL), Leipzig University (DE), Stanford University (US)
Good health and well-being
Meta-analysis and systematic reviews
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon